English
French
Loxapine bar
 |
Schizophrenia (Lozapine) |
|
|
|
Loxapine
INDICATED FOR SCHIZOPHRENIA & BIPOLAR 1 DISORDER
Loxapine VersaFilm® is the first innovative oral loxapine thin film for use in patients with schizophrenia- and bipolar 1 disorder-associated agitation. Loxapine VersaFilm® utilizes IntelGenx' proprietary VersaFilm® technology, allowing for an improved drug product which addresses unmet medicals needs in schizophrenia and bipolar 1 disorder.
Agitation associated with schizophrenia or bipolar mania can, if left untreated, rapidly escalate into physically aggressive behavior that can be potentially dangerous to the agitated individual and others. In a clinical setting, agitation associated with schizophrenia and bipolar mania are often managed with loxapine, a well-known antipsychotic medication.
middle icons
successful buccal
absorption pilot study
orally disintegrating
film
rapid onset of action
Loxapine is currently available in two dosage forms: (1) An inhaled version of vaporized loxapine for direct administration to the lungs, approved by the U.S. Food and Drug Administration in 2012, is indicated for the treatment of acute agitation associated with schizophrenia or bipolar 1 disorder in adults. The inhaled loxapine powder is associated with potentially life-threatening bronchospasms, limiting its administration in the U.S. to clinical settings associated with a Risk Evaluation and Mitigation Strategy (REMS) program. Under such program, the inhaled loxapine must be administered only in an enrolled healthcare facility, and to patients that have been pre-screened to ensure they are not susceptible to pulmonary issues. (2) An oral dosage form of loxapine has been available since 1975 and indicated for the treatment of schizophrenia. The loxapine capsules are unsuitable for treating acute agitation associated with schizophrenia or bipolar 1 disorder because the delayed onset of relief, which occurs approximately 20-30 minutes after administration, would significantly increase the risk of injury to a person being treated and those administering treatment.
loxapine vs
|
|||
|
|
||
Pocket size pouch provides unprecedented convenience
Does not require the patient to swallow a pill or consume water
middle text
In a successful pilot study, IntelGenx demonstrated that buccal drug absorption of loxapine VersaFilm® results in a significantly higher bioavailability compared to oral capsules. In addition, the orally disintegrating film does not need to be taken with water, and its on-the-go pocket-sized pouch provides unprecedented convenience for patients suffering from agitation.
IntelGenx has submitted a U.S. patent application for an oral film dosage form containing loxapine for the treatment of anxiety and aggression in patients suffering from schizophrenia or bipolar 1 disorder, potentially offering 20 years intellectual property protection.
Global schizophrenia drugs sales were estimated at $6.8 billion in 2018 and by 2026, the market is forecast to grow to $9.5 billion.1
Loxa Button
bottom text
PARTNER WITH US >>
IntelGenx plans to establish a strategic partnership for the development and subsequent commercialization of a branded differentiated loxapine film product, loxapine VersaFilm®.
Product Warning
PRODUCT WARNING
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
PRESCRIBING INFORMATION
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.